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ABSTRACT
Objective(s): The signiﬁcant contribution of nanoparticles to cancer treatment has attracted therapeutic 
attention. The present study aimed to evaluate the synergistic effects of 5-fluorouracil (5-FU) and zinc oxide 
nanoparticles (ZnO NPs) as multimodal drug delivery on human breast cancer MCF-7 cells.
Materials and Methods: In this in-vitro study, the impact of 5-FU and ZnO NPs in the single or combined 
forms was evaluated on cell viability, colony formation, apoptosis, p53 gene expression, and Bcl-2 signaling 
protein in MCF-7 breast cancer cell line using several techniques, such as MTT, clonogenic assay, flow 
cytometry, real-time quantitative polymerase chain reaction, and Western blot.
Results: In this study, 5-FU combined with ZnO NPs showed synergistic effects against MCF-7 within 48 
hours. In addition, the combination of 5-FU and ZnO NPs at the respective concentrations of 1 µM and 45 
µg/ml exhibited significant apoptosis (79.53%), p53 gene expression (3.6 folds), reduction of cell invasion 
(9.82%), and plating efficiency (5%), thereby leading to the significant reduction of cell viability (40±0.9%) 
and decreased Bcl-2 anti-apoptotic protein relative to untreated control cells. 
Conclusion: According to the results, the synergistic effects of combined ZnO NPs and 5-FU on MCF-7 
human breast cancer cells were exerted via Bcl-2 inhibition and the up-regulation of p53 expression.
Keywords: Bcl-2, p53 expression, Zinc oxide naoparticles, 5-Fluorouracil
INTRODUCTION
Breast cancer is the second most prevalent 
cancer among women across the world, accounting 
for 25% of the diagnosed human malignancies 
and 15% of cancer-related deaths [1, 2]”ISBN” : 
“00079235”, “ISSN” : “1542-4863 (Electronic. The 
incidence of invasive breast cancer was expected 
to reach 266,120 new diagnosed cases in 2018 [3]. 
Breast cancer is more prevalent in women aged 35-
70 years. The prevalence of breast cancer in Asia 
is reported to be four-fold compared to Western 
countries. The known risk factors for breast cancer 
include family history, pregnancy at old age, 
late menopause, early menstruation, long-term 
use of female hormones (e.g., contraceptives), 
and alcohol consumption [4]. Some of the main 
approaches to the treatment of breast cancer 
include radiotherapy, chemotherapy, hormone 
therapy (i.e., endocrine therapy), and targeted 
therapy. The main intervening therapeutic 
decisional indices are considered to be the cancer 
stage, grade of invasiveness, patient’s age, and 
underlying health status [5]. 
Chemotherapy is often used as an adjuvant 
or neoadjuvant treatment for breast cancer. 
Nevertheless, the complications of chemotherapy 
have paved the way for the investigation of new 
drug combination strategies [6]. Reducing the 
complications of chemotherapy in terms of 
the synergistic impact of drug combination is 
based on decreasing the required therapeutic 
dose of classical chemotherapy agents, such as 
5-fluorouracil (5-FU) [7]. This agent exerts anti-
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cancer effects by inhibiting and disrupting the DNA 
synthesis and functions. However, 5-FU resistance 
remains a major therapeutic challenge [8]. 
Various nanoparticles has been developed 
in order to provide new therapeutic alternatives 
with enhanced clinical effectiveness [9]surface 
coating, and cosmetics, and recently, they 
have been explored in biologic and biomedical 
applications. Therefore, this study was undertaken 
to investigate the effect of ZnO NPs on cytotoxicity, 
apoptosis, and autophagy in human ovarian 
cancer cells (SKOV3. Zinc oxide nanoparticles 
(ZnO NPs) have been reported to have promising 
anti-cancer properties through superior cancer 
cell penetration, targeting the salient cell cancer 
proliferation cycles, covering a large area of 
malignant cell membranes, and enhancing the 
availability of chemotherapy drugs [10]. ZnO NPs 
alter the production of reactive oxygen species 
(ROS), p53 gene expression, caspase-3 enzyme 
synthesis, Bcl-2 signaling pathway, and cell death. 
The present study aimed to investigate the 
effects of separate and combined treatments with 
5-FU and ZnO NPs on MCF-7 human breast cancer 
cells on cell growth and proliferation, p53 gene 
expression, and Bcl-2 signaling activity [11]. 
MATERIALS AND METHODS 
Cell culture
In this in-vitro study, human breast 
adenocarcinoma (MCF-7) cells were obtained from 
Pasteur Institute (Tehran, Iran). The cells were 
cultured in Dulbecco’s modified Eagle’s medium 
(DMEM; Gibco-Invitrogen) supplemented with 
10% fetal bovine serum (Gibco-Invitrogen), 100 
U/ml of penicillin/streptomycin Gibco (Rockville, 
MD, USA), and 1% L-glutamine in standard 
culture conditions (5% CO2, 98% humidity, 
and temperature of 37ºC) [12]recurrence, and 
metastasis formation. Salinomycin (SAL. 
The study protocol was approved by the Ethics 
Committee of Shahrekord University of Medical 
Sciences in Shahrekord, Iran (code: IR.SKUMS.
REC.1396.144).
Preparation of 5-FU and ZnO NPs
Initially, 5-FU was purchased from Haupt 
Pharma (Wolfratshausen GmbH Company, 
Germany) and diluted in the DMEM medium in 
order to obtain the concentrations of 0-11 µM 
[13]. ZnO NPs (10-30 nm, surface area: 20-60 m2/g) 
were purchased in the form of powder from Iranian 
Nanomaterials Pioneers Company (Mashhad, Iran) 
and suspended in phosphate-buffered saline (PBS) 
in order to achieve the ZnO NP stock solution of 
1,000 µg/ml. The stock solution was used to obtain 
the desired concentrations (0-110 µg/ml). 
MTT assay
At this stage, 3-(4, 5-dimethylthiazol-2yl)-2, 
5-diphenyltetrazolium bromide (MTT) assay was 
applied to evaluate MCF-7 cell viability. To this 
end, 5×103 cells per well (1.8×106 cells/ml) were 
seeded in 96-well plates, incubated overnight, and 
treated with various concentrations of 5-FU (0-11 
µM) or ZnONPs (0-110 µg/ml) for 48 hours. As for 
combined therapy, the cells were treated with four 
selected concentrations (Table 1). 
At the next stage, the MTT solution (5 mg/ml) 
was added to each well, which were incubated for 
four hours following incubation with DMSO (150 
µL) for 20 minutes. The absorbance of each well 
was measured using a microplate reader (model: 
Stat Fax-2100, Spain) at the wavelengths of 490-
570 nanometers. The rate of cell viability was 
expressed as the absorbance of the treated cells 
to the untreated control cells. The experiments 
were performed at least three times on three 
different days [14]. 
Clonogenic assay
MCF-7 cells were seeded in six-well plates and 
incubated overnight in six replicates. Afterwards, 
the cultured cells were treated with 1 µM of 
5-FU, 45 µg/ml of ZnO NPs, and the combination 
of 5-FU and ZnO NPs for 48 hours (Table 1). After 
the treatment, the cells were incubated at the 
temperature of 37ºC in 5% CO2 for 14 days for 
colony formation, and the medium was changed 
every 48 hours. Visible colonies were fixed with 
70% ethanol and stained with 0.5% crystal violet. 
In addition, the plating efficiency was measured 
[15].
Annexin V-PI staining for apoptosis assay
MCF-7 cells were seeded in six-well plates at 
the density of 2×105 cell/well and incubated for 
24 hours. When the cells reached 70% confluence, 
they were treated with 1 µM of 5-FU, 45 µg/ml 
of ZnO NPs, and the combination of 5-FU and 
ZnO NPs for 48 hours. Following that, all the cells 
(dead and viable) were collected by trypsination, 
washed with PBS, and stained with Annexin V (BD 
Bioscience California, USA) for 30 minutes at room 
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temperature. The cells were analyzed using the 
CYFLOW space (PARTEK, Germany) in accordance 
with the instructions of the manufacturer [16, 17]. 
Real-time polymerase chain reaction (PCR)
MCF-7 cells were seeded at the density of 6×105 
cell/well for 24 hours and exposed to the IC40 of 
ZnO NPs, IC10 of 5-FU, and their combination (1 µM 
of 5-FU and 45 µg/ml of ZnO NPs). Afterwards, the 
cells were harvested and lysed with Roti®ZOL (Carl 
Roth GmbH, Germany) based on the instructions 
of the manufacturer. In each treatment, the 
concentration of mRNA was determined using 
Nanodrop (Thermo-USA). 
At the next stage, cDNA was synthesized 
from one microgram of total mRNA using reverse 
transcriptase (Takara Bio Inc., Japan) in accordance 
with the instructions of manufacturer. Quantitative 
real-time polymerase chain reaction (RT-PCR) was 
performed using SYBR® green PCR master mix 
(Qiagen, Germany). During the RT-qPCR, cDNA 
was amplified using Rotor-Gene3000 (Corbett, 
Australia) in the presence of SYBR® green PCR 
master mix, the sequences of specific p53 primer 
sets (forward: 5’-CCCATCCTCACCATCATCACAC-3’, 
reverse:5’-GCACAAACACGCACCTCAAAG-3’),and 
glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH; forward: 5’- ACACCCACTCCTCCACCCTTTG-
3’,reverse:5’-GTCCACCACCCTGTTGCTGTA-3’)in 
each reaction. The primers were designed using 
the Oligo 7.0 software (Molecular Biology Insights, 
Cascade, Co.) and confirmed by blast (NCBI). 
The primers were purchased from Eurogentec 
(Seraing, Belgium). 
The temperature profile of each reaction was 
adjusted. Initially, denaturation was performed 
at the temperature of 95°C for 10 minutes in 40 
cycles based on a three-step program (10 seconds 
at 95°C, 15 seconds at 60°C, and 20 seconds at 
72°C). GAPDH was used as the housekeeping gene 
to normalize the gene expression data [18]. 
Western blot assay
MCF-7 cells were seeded at the density of 
6×105 cell/well for 24 hours and exposed to the 
IC40 of ZnO NPs, IC10 of 5-FU, and their combination 
(1 µM of 5-FU and 45 µg/ml of ZnO NPs). Following 
that, the cells were harvested and subsequently 
were lysed in ice-cold RIPA buffer (50 mM of Tris-
HCl, pH of 8.0, 150 mM of NaCl, 0.5% sodium 
deoxycholate, and 0.1% sodium dodecyl sulfate 
[SDS]) containing protease inhibitors, phosphatase 
inhibitor, and phenylmethylsulfonyl fluoride. The 
protein content was evaluated using the Bradford 
protein assay [19]. 
At this stage, 40 micrograms of protein 
was loaded in 10% SDS-PAGE and transferred 
to the polyvinylidene fluoride membrane. The 
membranes were incubated at the temperature 
of 4°C overnight using Bcl-2 and β-actin primary 
antibodies (Elabscience Biotechnology Co., 
Wuhan, China). Immunoblots were detected using 
horseradish peroxidase conjugated secondary 
antibody [20]. Band intensity was evaluated using 
chemiluminescent reagents (ECL; Thermo Fisher 
Scientific, USA) and analyzed using the Image J 
software.
Invasion assay
MCF-7 cells were seeded in six-well plates at 
the density of 2×105 cell/well with 1 µM of 5-FU, 
45 µg/ml of ZnO NPs, and their combination (1 µM 
of 5-FU and 45 µg/ml of ZnO NPs) for 48 hours. 
Afterwards, the invasion assay was performed as 
previously described [20].
Statistical analysis
Data analysis was performed using SPSS version 
20.0 (SPSS, Chicago, IL, USA) and GraphPad Prism 
6 (GraphPad Software Inc., San. Diego, CA, USA). 
The experimental data were expressed as mean 
and standard deviation of the mean from a 
minimum of three independent experiments. 
Group comparison of the means was carried out 
using Kruskal-Wallis test and Dunn’s test, and 
the P-value of less than 0.05 was considered 
significant.
The analysis of the data on the relative gene 
expression was performed using the 2-∆∆Ct method. 
Melting curves were generated in order to ensure 
the purity of the amplification product of each 
reaction. Moreover, the Western blot experiments 
were carried out in triplicate. The combination 
index (CI) was calculated using the CompuSyn 
software (Combo SynInc, City, State, USA), and 
CI of less than one, one, and more than one 
indicated synergism, additive, and antagonism 
effects, respectively. 
RESULTS 
Cytotoxicity of combined 5-FU and ZnO NPs on 
MCF-7 cell proliferation
MCF-7 cells were treated with various 
concentrations of ZnO NPs (0-110 µg/ml) and 5-FU 
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(0-11 µM) (Fig 1) or different combinations of ZnO 
NPs and 5-FU for 48 hours (Table 1). 
Table 1. Viability Rate of MCF-7 Cell Line Treated with 
Combination of ZnO NPs and 5-FU after 48 Hours of Incubation
Data presented as mean±SD of at least three independent 
experiments; CI˂1, =1, and ˃1 indicated synergism, additive 
effects, and antagonism, respectively; aP<0.05 vs. combinations 
number 1 and 2
Moreover, ZnO NPs or 5-FU used in separate 
treatments could inhibit the growth and 
proliferation of MCF-7 cells in a dose-dependent 
manner (Fig 1). The obtained concentrations of 
ZnO NPs and 5-FU could inhibit MCF-7 cell viability 
by 10%, 20%, 30%, 40%, and 50% (IC10, IC20, IC30, 
IC40, and IC50 values, respectively). Afterwards, 
MCF-7 cells were treated with four combinations 
of ZnO NPs and 5-FU based on the selected values 
(Table 1).The combinations of ZnO NPs and 5-FU 
significantly decreased the cell viability of MCF-7 
cells compared to the single treatment with ZnO 
NPs or 5-FU (P<0.05) (Table 1). 
In addition, CI was calculated for the four 
combinations of ZnO NPs and 5-FU (Table 1). All 
the combinations resulted in the CI values of less 
than one, indicating synergistic effects.   
   
Effects of combined treatment with 5-FU and ZnO 
NPs on the colony formation potential of MCF-7 
cells
The colony formation potential of MCF-7 cells 
was determined after treatment with ZnO NPs 
(IC40), 5-FU (IC10), and the combination of ZnO 
NPs (IC40) and 5-FU (IC10) using the clonogenic 
assay. According to the findings, ZnO NPs (IC40) 
and the combination of ZnO NPs (IC40) and 5-FU 
(IC10) significantly inhibited the colony formation 
potential of MCF-7 cells compared to the untreated 
control cells (P<0.05). 
The rate of plating efficiency was estimated at 
33%, 10%, 18%, and 5% in the untreated control 
cells, cells treated with ZnO NPs (IC40), cells 
treated with 5-FU (IC10), and cells treated with 
the combination of ZnO NPs (IC40) and 5-FU (IC10), 
respectively (Fig 2). Moreover, the combination of 
ZnO NPs (IC40) and 5-FU (IC10) induced the highest 
significant inhibition in the colony formation 
potential compared to the single treatment with 
5-FU (IC10) (P<0.05). 
No significant difference was observed 
between the cells treated with ZnO NPs (IC40) and 
5-FU (IC10) (P>0.05). Furthermore, no significant 
difference was observed between the cells treated 
with combined ZnO NPs and 5-FU (1 µM of 5-FU 
and 45 µg/ml of ZnO NPs) and single treatment 
of ZnO NPs (IC40, 45 µg/ml) in terms of the colony 
formation and rate of plating efficiency (P>0.05).  
Effects of Combined 5-FU and ZnO NPs on the 
Apoptosis induction of MCF-7 cells
MCF-7 cells were treated with ZnO NPs (IC40), 
5-FU (IC10), and the combination of ZnO NPs (IC40) 
and 5-FU (IC10) using Annexin V-PI staining in order 
to measure the rate of apoptotic and necrotic cells 
(Fig 3). The results of Annexin V-PI assay indicated 
that the single treatment with ZnO NPs (IC40) 
or 5-FU (IC10) induced apoptosis in MCF-7 cells. 
However, the combination treatment with ZnO 
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Number of 
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Dose Combination  
Cell Viability±SD 
 
CI 
ZnO NPs (IC), g/ml 5-FU (IC), M 
1 8 (IC10) 6 (IC40) 52±0.61 0.59 
2 12 (IC20) 3 (IC30) 57±0.46 0.65 
3 20 (IC30) 1.5 (IC20) 54±1.2 0.36 
4 45 (IC40) 1 (IC10) 40±0.9 0.21
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Fig 1. Rate of Cell Viability in MCF-7 Cells after Treatment with Various Concentrations of ZnO NPs (a) and 5-FU (b) for 48 Hours 
(data expressed as mean±SD of at least three independent experiments)
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NPs (IC40) and 5-FU (1 µM) caused a significant 
elevation in the rate of apoptosis (79.53%) 
compared to the untreated control cells (P<0.05) 
(Fig 3). 
Moreover, no significant difference was 
observed between the cells treated with combined 
ZnO NPs and 5-FU compared to those with the 
single treatment of ZnO NPs (IC40, 45 µg/ml) in 
terms of apoptosis (P>0.05). 
Effects of single and combined treatment with 
5-FU and ZnO NPs on apoptosis-related gene 
expression and MCF-7 cell invasion
Fig 4 shows the effects of single and combined 
treatment with 5-FU and ZnO NPs on p53 gene 
expression in MCF-7 cells. P53 gene expression 
significantly increased in the cells with the 
combined treatment (3.6-fold) compared to the 
untreated control cells (P<0.05). 
2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 2. Clonogenic Formation of MCF-7 Cells after Treatment with ZnO NPs (45 µg/ml), 5-FU (1 µM) or combination of ZnO NPs (45 µg/
ml) and 5-FU (1 µM) Using Clonogenic Assay (Clonogenic assay was conducted 14 days after the treatment; A: a) untreated cells, b) 
treated cells with IC10 of 5-FU [1 µM], c) treated cells with IC40 of ZnO NPs [45 µg/ml], d) treated cells with IC10 of 5-FU [1 µM] and 
IC40 of ZnO NPs [45 µg/ml]; B; Rate of plating efficiency in MCF-7 cells; data expressed as mean±SD of at least three independent 
experiments; aP<0.05 vs. control cells, bP<0.05 vs. 5-FU)
3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3. A: Annexin V-FITC/PI Analyzed by Flow Cytometry, B: Rate of Total Apoptosis Cells Treated with ZnO NPs (45 µg/ml), 5-FU (1 
µM) or Combination of ZnO NPs (45 µg/ml) and 5-FU (1 µM) for 48 Hours (data expressed as mean±SD of at least three independent 
experiments; aP<0.05 vs. control cells, bP<0.05 vs. 5-FU)
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Moreover, the expression of p53 was 
significantly higher in the MCF-7 cells with 
combined treatment compared to those with the 
single treatment of 5-FU (P<0.05). On the other 
hand, no significant difference was observed 
between the single treatment with ZnO NPs 
(IC40, 45 µg/ml) and combined ZnO NP and 5-FU 
treatment in terms of the p53 gene expression in 
the cells (P>0.05). 
Western blot was used to measure the cellular 
Bcl-2 level in MCF-7 cells after 48 hours (Fig 
5). The anti-apoptotic protein Bcl-2 decreased 
significantly following the combined treatment 
of the cells with ZnO NPs (IC40) and 5-FU (IC10) 
compared to the untreated control cells, as well 
as the cells treated with 5-FU only (P< 0.05). In 
addition, no significant difference was observed in 
the Bcl-2 levels between the cells with combined 
ZnO NP (IC40) and 5-FU treatment (IC10) and those 
with the single treatment of ZnO NPs (IC40, 45 µg/
ml) (P>0.05). Fig 6 depicts the effects of ZnO NPs 
(IC40), 5-FU (IC10), and their combination on the 
invasion of MCF-7 cells. 
Accordingly, the invasion of the MCF-7 cells 
that were with ZnO NPs (IC40), 5-FU (IC10), and their 
combination significantly reduced compared to 
the untreated cells by 21.37%, 61.2%, and 9.82%, 
respectively. 
Fig 4. Changes in P53 Gene Expression Treated with ZnO NPs 
(45 µg/ml), 5-FU (1 µM) or Combination of ZnO NPs (45 µg/
ml) and 5-FU (1 µM) for 48 Hours (data expressed as mean±SD 
of at least three independent experiments; aP<0.05 vs. control 
cells, bP<0.05 vs. 5-FU)
DISCUSSION
Multimodal drug combination has gained 
pertinent consideration in anti-cancer therapeutic 
approaches [21]as well as the do’s and don’ts 
in drug combination studies, in terms of 
experimental design, data acquisition, data 
interpretation, and computerized simulation. 
The Chou-Talalay method for drug combination 
is based on the median-effect equation, derived 
from the mass-action law principle, which is the 
unified theory that provides the common link 
between single entity and multiple entities, and 
first order and higher order dynamics. This general 
equation encompasses the Michaelis-Menten, Hill, 
Henderson-Hasselbalch, and Scatchard equations 
in biochemistry and biophysics. The resulting 
combination index (CI. The current research aimed 
to investigate the anti-cancer effects of 5-FU and 
ZnO NPs on MCF-7 cells as separate or combined 
treatment in an in-vitro setting. Our findings 
are consistent with the previous studies in this 
regard, including the reports on the synergistic, 
anti-cancer effects on MCF-7 cells. For instance, 
Sanad et al. reported the enhanced effectiveness 
of 5-FU in MCF-7 cells through the adherence of 
ZnO NPs to the 5-FU surface, while presenting no 
data on colony formation, Western blot, and cell 
invasiveness [22]. Furthermore, the mechanism 
of ZnO NP cytotoxicity was assumed to be exerted 
through cell endocytosis, leading to cytoplasmic 
aggregation [23]. 
ZnO NPs are inorganic compounds reported 
to inhibit the growth of MCF-7 cells by inducing 
apoptosis [18]. In this regard, Deng et al. used 
ZnO NPs in adjunction to ultraviolet radiation, 
demonstrating enhanced intra SMMC-7721 cell 
doxorubicin concentration, which in turn induced 
the inhibition of cancer cell growth [24]. In line 
with the latter, the cellular uptake of daunorubicin 
was reported to be facilitated  by ZnO NPs in the 
setting of K562 and K562/A02 leukemia cancer 
cells [25]. Therefore, it could be inferred that the 
dosage of ZnO NPs exerts its anti-cancer effects by 
facilitating the cellular uptake of chemotherapy 
agents. On the other hand, ZnO NP dose could 
enhance cellular oxidative stress, destroy cell 
organelles (e.g., DNA, RNA, and endoplasmic 
reticulum), and induce apoptosis [18, 26]. 
5-FU is an anti-cancer agent used in the 
treatment of various cancer types owing to its 
antimetabolite properties by incorporating DNA 
(in the place of thymine) or RNA (in the place of 
uracil) and inducing cell apoptosis [27]; however, 
therapeutic resistance to 5-FU remains a challenge 
in the clinical setting. In the present study, the 
in-vitro effects of separate or molecule-free 
5-FU/ZnO NPs were assessed in a free-molecule 
combination on MCF-7 cells using the clonogenic 
assay, Western blot, and invasion methods. In 
contrast to the previous findings regarding the 
surface insertion of ZnO NPs onto 5-FU molecules, 
the combination of 5-FU and ZnO NPs showed 
superior anti-cancer cell effectiveness compared 
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to the separate treatment with each of these 
agents. This is consistent with the previous study 
in this regard [22].
In the current research, the four titrations of 
5-FU/ZnO NPs combination demonstrated the 
presumed synergistic effects based on specified 
CI value and MTT data (Table 1). In addition, the 
extent of synergism varied depending on the ratio 
of the 5-FU/ZnO NP concentrations used in the 
combination therapy. The observed reduction 
in cell proliferation was in line with the previous 
findings in this regard, indicating the facilitating 
role of drug delivery (e.g., nano-based drug 
delivery) in 5-FU effectiveness [28, 29]. 
The long-term cytotoxicity of 5-FU/ZnO NP 
combination number four (Table 1; ZnO NPs at 
IC40 and 5-FU at IC10) was also assessed using the 
clonogenic assay after 14 days. The latter was 
observed to inhibit the colony formation of MCF-
7 cells more significantly compared to the single 
treatment with 5-FU or ZnONPs (Fig 2). As a result, 
cell growth inhibition was sustained by the expected 
synergistic effects of ZnONPs on 5-FU. Moreover, 
MCF-7 cell apoptosis was assessed using flow 
cytometry, and the obtained results indicated that 
5-FU/ZnO NP combination number four induced 
the highest apoptotic ratio (Fig 3), confirming the 
presumed synergistic effects. In this regard, Deng 
et al. reported that ZnONPs could induce p53 gene 
expression, thereby leading to apoptosis in human 
malignancies [24]surface coating, and cosmetics, 
and recently, they have been explored in biologic 
and biomedical applications. Therefore, this study 
was undertaken to investigate the effect of ZnO 
NPs on cytotoxicity, apoptosis, and autophagy in 
human ovarian cancer cells (SKOV3. 
Several studies have demonstrated that the 
combination of ZnONPs with chemotherapy 
agents induced apoptosis through the activation of 
caspase-3, caspase-8, and caspase-9 release from 
cytochrome c and down-regulation of Bcl-2 [9, 24]
surface coating, and cosmetics, and recently, they 
have been explored in biologic and biomedical 
applications. Therefore, this study was undertaken 
to investigate the effect of ZnO NPs on cytotoxicity, 
apoptosis, and autophagy in human ovarian cancer 
cells (SKOV3, which is in line with the results of the 
present study. In the current research, p53 gene 
expression significantly enhanced based on the 
results of RT-PCR, which in turn led to MCF-7 cell 
death via mediating apoptosis using the 5-FU/
ZnONP combination number four (ZnONPs at IC40 
and 5-FU at IC10) (Fig 4). Evading apoptosis is a 
therapeutic issue associated with the production 
of nonfunctional p53 protein or up-regulation of 
the Bcl-2 family of anti-apoptotic proteins [30]. The 
tumor suppressor gene p53 stimulates a network 
of signals, which act via apoptotic pathways [31].
Fig 5. A: Western Blot Image of Bcl-2 and B-action after 
Treatment with Combination of ZnO NPs (45 µg/ml) and 
5-FU (1 µM) and Single Treatment with ZnO NPs or 5-FU for 
48 Hours; B: Densitometry Calculations for Western Blot Data 
Using Image J (aP<0.05 vs. control cells, bP<0.05 vs. 5-FU)
Fig 6. A: Effects of ZnO NPs, 5-FU, and Their Combination on 
MCF-7 Cell Invasion for 48 Hours; B: Treated MCF-7 Cells for 48 
Hours with ZnO NPs (45 µg/ml), 5-FU (1 µM) or Combination 
of ZnO NPs (45 µg/ml) and 5-FU (1 µM) (Invading cells were 
counted using inverted microscope bars; aP<0.05 vs. control 
cells, bP<0.05 vs. 5-FU)
According to the findings of the current 
research, MCF-7 cell viability reduced based on 
the MTT assay (Fig 1), which is inconsistent with 
the previous findings in this regard, denoting the 
role of p53 protein in apoptosis induction [8, 32]. 
An in-vitro study in this regard demonstrated the 
elevation of p53 gene expression by inserting 
ZnO NPs onto the surface of 5-FU (ZnO NPs and 
5-FU) in the same setting of MCF-7 cells [22]. P53 
regulates the cell cycle by acting as a major anti-
cancer barrier [32]. According to the literature, 
ZnO NPs could induce cell apoptosis, and the p53 
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activity accompanied by reducing Bcl-2 proto-
oncogene [33, 34]. The results of the present study 
indicated a significant reduction in the level of Bcl-
2 expression in the MCF-7 cells that were treated 
with combination number four of 5-FU and ZnO 
NPs. Apoptosis increases in various cancer cells 
due to Bcl-2 inhibition [35], which is accompanied 
by cell growth inhibition; this is in congruence with 
our findings (Fig 5). Meanwhile, the combination 
of 5-FU and ZnO NPs was observed to inhibit the 
invasion of the MCF-7 cell line (Fig 6), thereby 
resulting in the inhibition of MCF-7 colony 
formation. Therefore, it could be concluded that 
the elevation of p53 gene expression, along with 
the reduction of Bcl-2 and cellular invasion, were 
resulted from the combination treatment with 
5-FU and ZnO NPs.  
CONCLUSION
According to the results of this in-vitro study, 
the synergistic effects of ZnO NPs and 5-FU 
combination therapy on MCF-7 human breast 
cancer cells were exerted via Bcl-2 inhibition and 
the up-regulation of p53 expression, which also 
decreased cell invasion to a lesser extent. 
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